Effect of Pharmaceutical Care on patients with Chronic Pai
Not Applicable
Recruiting
- Conditions
- Arthritis, RheumatoidFibromyalgiaC05.550.114.606
- Registration Number
- RBR-8494rf7
- Lead Sponsor
- niversidade Federal de Sergipe
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Patients previously diagnosed with rheumatoid arthritis and/or fibromyalgia, according to the diagnostic criteria of the American College of Rheumatology. Patients of both gender. Aged over 18 years. Who have been using pharmacotherapy prescribed for rheumatoid arthritis for at least 6 months, and/or pharmacotherapy prescribed for fibromyalgia for at least 1 month
Exclusion Criteria
Patients with severe psychiatric disorders; cancer; pregnant women; those participating in other clinical trials that have the same outcomes or interventions that may cause a risk of bias
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcomes evaluated will be quality of life and pain intensity. To assess health-related quality of life (HRQoL), the Portuguese version of the European quality of life scale (EQ-5D) will be used. To assess pain intensity, the visual analogue scale (VAS) will be used.
- Secondary Outcome Measures
Name Time Method Secondary outcomes will be adherence to pharmacotherapy, patient satisfaction and medication-related problems. To assess adherence to pharmacotherapy, an adaptation of the four-item Therapeutic Adherence Scale will be used. To carry out the assessment of drug-related problems (DRP), the four-item classification will be used. To assess patient satisfaction, the Net Promoter Score (NPS) method will be used.